Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget | Kinase Activity in Renal Cell Carcinoma, Benign Renal Tissue and in Response to Tyrosine Kinase Inhibitors

Oncotarget

August 17, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on August 4, 2022, entitled, “Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.” continue reading »

Oncotarget | Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma

News

August 11, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on August 3, 2022, entitled, “Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.” continue reading »

Oncotarget | A Novel Mechanism of Regulation of the Oncogenic Transcription Factor GLI3 by Toll-like Receptor Signaling

News

August 9, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on August 3, 2022, entitled, “A novel mechanism of regulation of the oncogenic transcription factor GLI3 by toll-like receptor signaling.” continue reading »

Does a Mechanism Linking Cellular Aging to Cellular Quiescence Exist?

Oncotarget

August 5, 2022
Researchers found that diverse geroprotectors differently affect a mechanism linking cellular aging to cellular quiescence in budding yeast. continue reading »

Oncotarget | Chemoradiation Alters PD-L1, CD8+ TILs and Mucin in Rectal Cancer

News

August 2, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on July 28, 2022, entitled, “Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.” continue reading »